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OBJECTIVES We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the
occurrence of myocardial ischemia in patients with microvascular angina attributable to
coronary microvascular spasm.
BACKGROUND Effective treatment of patients with angina who have normal coronary arteriograms
(microvascular angina) has not yet been established. Rho-kinase–mediated calcium sensiti-
zation of the myosin light chain in smooth muscle cells has been implicated as substantially
contributing to vascular hyperconstriction.
METHODS We studied consecutive 18 patients with angina and normal epicardial coronaries in whom
intracoronary acetylcholine (ACh) induced myocardial ischemia (ischemic electrocardio-
graphic changes, myocardial lactate production, or both) without angiographically demon-
strable epicardial coronary vasospasm. All patients underwent a second ACh challenge test
after pretreatment with either saline (n  5) or fasudil (4.5 mg intracoronarily, n  13).
RESULTS Myocardial ischemia was reproducibly induced by ACh in the saline group. In contrast, 11 of
the 13 patients pretreated with fasudil had no evidence of myocardial ischemia during the
second infusion of ACh (p  0.01). The lactate extraction ratio (median value [interquartile
range]) during ACh infusion was improved by fasudil pretreatment, from 0.16 (0.25 to
0.04) to 0.09 (0.05 to 0.18) (p  0.0125).
CONCLUSIONS Fasudil ameliorated myocardial ischemia in patients who were most likely having coronary
microvascular spasm. The inhibition of Rho-kinase may be a novel therapeutic strategy for
this group of patients with microvascular angina. (J Am Coll Cardiol 2003;41:15–9)
© 2003 by the American College of Cardiology Foundation
Angina with normal coronary arteriograms (cardiac syn-
drome X or microvascular angina) still remains a dilemma
both for patients and physicians. It has posed a long-lasting
health care problem, because many patients continue to
have chest pain and even be disabled while taking conven-
tional anti-anginal medications (1). Effective treatment has
not been established, at least partly because it may include
divergent clinical entities (2). We and others have reported
that myocardial ischemia caused by abnormal microvascular
constriction (spasm) might be the cause of chest pain in a
subset of patients with microvascular angina (3–5). The
prevention of microvascular spasm may therefore be a
rational approach in these patients.
Rho-kinase modulates calcium sensitivity of the myosin
light chain in smooth muscle cells (6) and has been
implicated as playing a pathogenetic role in divergent
cardiovascular disorders (7). Within this context, we re-
cently demonstrated that the Rho-kinase–mediated path-
way is majorly involved in the pathogenesis of epicardial
coronary artery spasm in pigs (8,9) and in patients with
vasospastic angina (10). In the present study, we tested the
hypothesis that a Rho-kinase inhibitor might be effective in
preventing myocardial ischemia in patients with microvas-
cular angina attributable to coronary microvascular spasm.
METHODS
Patients. Eighteen patients with angina who underwent
diagnostic cardiac catheterization, with a diagnosis of mi-
crovascular angina between January 1999 and December
2000, participated in the study. Clinical and angiographic
features are summarized in Table 1. All patients were female
and had angina at rest, on effort, or both. Seven of the 18
patients had been treated with calcium antagonists before
admission; calcium antagonists were effective in two of these
patients, partially effective in three, and ineffective in two.
No patient had significant (50%) organic stenosis in any
major epicardial coronary artery or a history of revascular-
ization procedures, severe valvular heart disease, idiopathic
dilated or hypertrophic cardiomyopathy, or chronic renal
failure. The study protocol was approved by the Institu-
tional Ethical Committee on Human Research. We ob-
tained written, informed consent from each patient before
the study.
Study protocol. Cardiac catheterization was performed in
patients in the fasting state after 5 mg oral diazepam. No
patient had ever been on long-acting calcium channel
blockers or hormone replacement therapy, and all cardio-
vascular medications, except sublingual nitroglycerin, were
discontinued at least 24 h before the study. Coronary
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arteriography was done by the femoral approach. A 6F
pacing catheter was placed in the right ventricle to prevent
bradycardia during acetylcholine (ACh) infusion. Another
6F catheter was advanced into the coronary sinus vein to
sample blood for measurement of lactate concentrations.
The diagnostic protocol for coronary microvascular spasm
was reported previously (5,11). Briefly, graded doses of ACh
(10, 30, and 100 g) were infused over 30 s into the left
coronary artery through a 6F Judkins catheter. At 1 min
after each dose of ACh was given, paired samples of 2 ml
blood were collected from the coronary artery and coronary
sinus vein for measurement of lactate concentrations. Bi-
plane coronary arteriograms were then taken to assess the
lumen diameter of large epicardial coronary segments.
When chest pain, electrocardiographic (ECG) changes, or
epicardial spasm did not occur, we gave the next dose of
ACh. We considered that chest pain was caused by myo-
cardial ischemia of microvascular origin when angina was
associated with evidence of myocardial ischemia (ischemic
ECG changes, myocardial lactate production, or both), but
without epicardial coronary artery spasm (5,11). Epicardial
coronary spasm was defined as 75% diameter reduction,
compared with the diameter after intracoronary isosorbide
dinitrate (ISDN) administration (5,12), and the subject who
had an epicardial spasm was excluded from the study.
When ACh induced chest pain and ischemic ECG
changes without angiographically demonstrable epicardial
spasm, we carefully observed the patient by continuously
monitoring the arterial blood pressure and 12-lead ECG
and by taking a coronary arteriogram at 1-min intervals to
confirm the absence of epicardial spasm. After the chest
pain and ECG changes had subsided spontaneously, pa-
tients were allocated to either the group receiving saline
(n  5) or fasudil (n  13). Saline or fasudil (300 g/min)
was infused over 15 min into the left coronary artery
through the Judkins catheter. Then, the same dose of ACh
that had provoked angina was infused for a re-challenge.
After the conclusion of the study, ISDN was administered
into the left coronary artery.
Drugs. We used the following drugs: fasudil (Asahi Chem-
ical Industries, Tokyo), ACh (Daiichi-Seiyaku, Tokyo), and
ISDN (Eisai, Tokyo). All drugs were diluted in physiologic
saline immediately before use. We have recently demon-
strated that with our dosing protocol of fasudil (300 g/min
for 15 min intracoronarily), the concentrations of fasudil
were raised to 3.7  0.4 (SD) mol/l in the coronary
circulation in patients without obstructive coronary artery
disease (10). This value is higher than the reported half-
maximal inhibitory concentration (IC50) of fasudil for Rho-
kinase inhibition (1.8 to 1.9 mol/l) (13).
Measurements. Quantitative coronary arteriography was
performed with a Siemens biplane cineangiographic system
(Bicor/Hicor, Siemens, Erlangen, Germany), as reported
(14,15). Measurements were taken at 10 segments of the left
coronary artery: left main trunk; proximal, middle, and
distal segments of the left anterior descending coronary
artery; first and second diagonal branches; proximal and
distal segments of the left circumflex artery; obtuse marginal
branch; and posterolateral branch. Segments that showed
the greatest constrictive response in the left anterior de-
scending coronary artery and left circumflex artery were used
for analysis. The degree of vasoconstriction was normalized
by the diameter obtained after ISDN administration and
was presented as the percent diameter reduction.
Electrocardiographic changes were considered ischemic
when transient ST-segment depression or elevation 0.1
mV at 80 ms after the J point was noted in at least two leads.
Lactate concentrations of sampled blood were immediately
determined with a lactate analyzer (2300 Stat Plus, YSI,
Yellow Springs, Ohio). The myocardial lactate extraction
ratio was calculated as the ratio of the coronary arterial-
venous difference in lactate concentration to the arterial
concentration. Myocardial lactate production (i.e., negative
extraction ratio) was considered to be evidence of myocar-
dial ischemia.
Statistics. Data are presented as the median value (inter-
quartile range). Comparisons of continuous variables were
done by using the Wilcoxon signed-rank test. Effects of
treatment (saline vs. fasudil) on the prevalence of angina and
myocardial ischemia during ACh infusion were analyzed by





ISDN  isosorbide dinitrate
Table 1. Clinical and Angiographic Features of the
18 Study Patients




Rest and effort 8 (44%)
Angina 30 min 7 (39%)
Positive exercise ECG 4 (22%)
Coronary risk factors
Hypertension 6 (33%)
Diabetes mellitus 1 (6%)
Current or past smoking 0 (0%)
Hypercholesterolemia 4 (22%)
Total cholesterol (mg/dl) 197 (181–208)
LDL cholesterol (mg/dl) 117 (97–133)
Maximal diameter stenosis* (%) 0 (0–19)
*Measured after administration of isosorbide dinitrate. Data are presented as the
median value (interquartile range) or number (%) of patients.
ECG  electrocardiogram; LDL  low-density lipoprotein.
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RESULTS
Acetylcholine challenge testing. During the first ACh
test, all 18 patients had chest pain and evidence of myocar-
dial ischemia without epicardial spasm (Table 2, Figs. 1 and
2).
In the saline group (n  5), both angina and myocardial
lactate production were reproducibly induced by the second
ACh challenge test. The myocardial lactate extraction ratio
during the first and second ACh infusions was unchanged
(0.13 [0.33 to0.09] vs.0.19 [0.42 to0.06]; p
NS). In the fasudil group (n  13), the second ACh
challenge did not provoke myocardial ischemia in 11 pa-
tients (p  0.01, saline vs. fasudil), although two of the 11
patients had chest pain. The remaining two patients had
anginal pain, ischemic ECG changes, and lactate produc-
Table 2. Prevalence of Angina and Ischemic Electrocardiographic Changes, Myocardial Lactate Metabolism, Systemic
Hemodynamics, and the Degree of Epicardial Constriction at Acetylcholine Testings
Saline (n  5) Fasudil (n  13)
First ACh Second ACh First ACh Second ACh
Angina 5 (100%) 5 (100%) 13 (100%) 4 (31%)‡
ECG changes 5 (100%) 4 (80%) 12 (92%) 2 (15%)§
Lactate production* 5 (100%) 5 (100%) 8 (80%) 2 (20%)‡
Lactate extraction ratio 0.13 (0.33 to 0.09) 0.19 (0.42 to 0.06) 0.16 (0.25 to 0.04) 0.09 (0.05 to 0.18)¶
Epicardial constriction (%)†
LAD 18 (34 to 14) 26 (30 to 17) 20 (40 to 13) 11 (32 to 7)
LCx 23 (24 to 21) 17 (23 to 14) 19 (26 to 11) 13 (21 to 7)
*Not determined in three patients in the fasudil group. †Expressed as the percent reduction in lumen diameter from that after nitrate administration. ‡p  0.05. §p  0.01 for
saline vs. fasudil (by the chi-square test). ¶p  0.013 for first ACh vs. second ACh (by the Wilcoxon signed-rank test). Data are shown as the number (%) of patients or median
value (interquartile range).
ACh  acetylcholine; ECG  electrocardiogram; LAD  left anterior descending coronary artery; LCx  left circumflex artery.
Figure 1. Representative coronary arteriograms and electrocardiographic (ECG) tracings (lead V4) of a patient from the fasudil group. (Top left) Baseline
coronary arteriogram shows a normal left coronary artery. (Top right) Acetylcholine (ACh) induced angina and downsloping ST-segment depression, but
no epicardial spasm. Lactate production was also noted. (Bottom left) The second ACh test after pretreatment with fasudil (F) did not provoke angina,
ischemic ECG changes, epicardial spasm, or lactate production. (Bottom right) Normal coronary arteriograms after administration of isosorbide dinitrate.
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tion during ACh infusion, even after pretreatment with
fasudil. Overall, fasudil pretreatment significantly improved
the myocardial lactate extraction ratio from 0.16 [0.25
to 0.04] to 0.09 [0.05 to 0.18] in the Fasudil group (p 
0.0125 by the Wilcoxon signed-rank test).
Hemodynamics and epicardial diameters. Systolic arterial
pressure and heart rate were comparable at the first and
second ACh administrations, both in the saline and fasudil
groups (data not shown). The magnitude of ACh-induced
epicardial coronary vasoconstriction was minimal and did
not differ between the first and second ACh challenges
(Table 2).
DISCUSSION
We demonstrated that intracoronary fasudil prevented
ACh-induced angina and myocardial ischemia in patients
with coronary microvascular spasm. Because this effect was
not associated with changes in systemic blood pressure,
heart rate, or the magnitude of epicardial coronary constric-
tion, it is suggested that fasudil suppressed ACh-induced
coronary microvascular hyperconstriction in our patients.
Mechanism of myocardial ischemia in microvascular
angina. The effective treatment of microvascular angina
has not been established, and a substantial proportion of
patients remain symptomatic even while taking conven-
tional anti-anginal medications (16–18). Recently, we re-
ported that coronary microvascular spasm and resultant
myocardial ischemia might be the cause of chest pain in a
subgroup of these patients (5). We have shown that angina
was associated with myocardial lactate production, definite
evidence of myocardial ischemia, but without epicardial
coronary artery hyperconstriction. Constrictive responses of
epicardial segments to ACh were minimal (25%) in our
patients, suggesting that myocardial ischemia was caused
primarily by coronary microvascular spasm.
Rho-kinase as a therapeutic target. To suppress micro-
vascular spasm, we have targeted Rho-kinase for the follow-
ing reasons. First, it has been shown that Rho-kinase-
mediated phosphorylation of myosin phosphatase plays a
central role in smooth muscle hypercontraction (6,7,19).
Second, we have demonstrated that a Rho-kinase inhibitor
such as fasudil and Y-27632 prevented epicardial coronary
vasospasm in the animal model (8,9) and in patients with
vasospastic angina (10). Third, we have recently shown that
Rho-kinase was involved in increased tone of peripheral
resistance vessels in hypertensive patients (20).
Fasudil has been shown to be a selective and potent
Rho-kinase inhibitor when tested in vitro and in animals
(8,13,21). As already mentioned in the Methods section,
our dosing protocol raised the concentrations of fasudil to
3.7 mol/l in the coronary circulation (10), which is higher
than the reported IC50 of fasudil for Rho-kinase inhibition
(1.8 to 1.9 mol/l) (13,22). In addition, we previously
demonstrated that a comparable dose of intracoronary
Fasudil inhibited the activity of myosin phosphatase, a
target protein of Rho-kinase, in pigs in vivo (23). These
lines of evidence suggest that the beneficial effect of fasudil
observed in the present study was brought about, in large
part, through the inhibition of Rho-kinase. Intriguingly,
abnormal hypercontraction of coronary microvessels has
been suggested to contribute to myocardial ischemia also in
patients with epicardial coronary artery disease (24,25).
Figure 2. Bar graphs showing the incidence of angina and evidence of myocardial ischemia (ischemic electrocardiographic [ECG] changes, lactate
production, or both) during the first (open bars) and second (solid bars) acetylcholine challenges. *p  0.05, **p  0.01, saline vs. fasudil (by the
chi-squared test).
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Whether the Rho-kinase inhibitor is effective in ameliorat-
ing myocardial ischemia in these patients remains to be
examined. Finally, it should be noted that patients enrolled
in the present study had objective evidence of myocardial
ischemia (i.e., lactate production). Therefore, our results do
not necessarily suggest a general use of Rho-kinase inhibi-
tors in patients with chest pain and normal epicardial
coronaries, but no evidence of myocardial ischemia.
Study limitations. First, coronary microvascular spasm was
not angiographically documented in our patients, and its
contribution to myocardial ischemia was only indirectly
suggested. However, as discussed earlier, it seems very
unlikely that other factors, such as epicardial constriction or
hemodynamic alterations, played a primary role in the
development of myocardial ischemia during ACh infusion.
Second, the long-term effect of Rho-kinase inhibition in
these patients is unknown. An orally active preparation of
fasudil is now under investigation and will be available in
the near future (26). Thus, trials are warranted to determine
whether oral fasudil improves the anginal status and/or the
quality of life in patients with angina caused by coronary
microvascular spasm.
Conclusions. Fasudil was effective in preventing ACh-
induced myocardial ischemia in patients with angina most
likely caused by hyperconstriction of coronary microvessels.
We suggest that inhibition of Rho-kinase may be a novel
therapeutic strategy for patients with microvascular angina
in whom coronary microvascular spasm is causatively in-
volved.
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